General | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Comparison | ||||||||||||||||||||||||||||
|
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-04-25 | 2024-03 | -1.49 | -1.32 | 0.17 | 11.41% |
2024-02-06 | 2023-12 | 1.76 | 1.72 | -0.04 | -2.27% |
2023-11-07 | 2023-09 | 1.91 | 2.29 | 0.38 | 19.90% |
2023-08-03 | 2023-06 | 1.6 | 1.34 | -0.26 | -16.25% |
2023-04-27 | 2023-03 | 1.63 | 1.37 | -0.26 | -15.95% |
2023-02-02 | 2022-12 | 1.5 | 1.67 | 0.17 | 11.33% |
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-09-07 | B of A Securities | Upgrade | Neutral | Buy |
2023-09-05 | Truist Securities | Upgrade | Buy | Buy |
2023-09-05 | HSBC | Upgrade | Reduce | |
2023-09-05 | Truist Securities | Upgrade | Buy | Buy |
2023-08-08 | Benchmark | Upgrade | Buy | Buy |
2023-08-03 | RBC Capital | Upgrade | Sector Perform | Sector Perform |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2024-05-07 | BARTON JACQUELINE K | Director | 24.54K | Stock Award(Grant) |
2024-03-07 | DICKINSON ANDREW D | Chief Financial Officer | 134.98K | Conversion of Exercise of derivative security |
2024-05-07 | LOVE TED WENDELL | Director | 2.82K | Stock Award(Grant) |
2024-05-07 | MANWANI HARISH | Director | 12.87K | Stock Award(Grant) |
2024-03-07 | MERCIER JOHANNA | Officer | 118.43K | Conversion of Exercise of derivative security |
2024-03-07 | O'DAY DANIEL PATRICK | Chief Executive Officer | 484.85K | Conversion of Exercise of derivative security |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Blackrock Inc. | 126.19M | 9.73B | 10.13% |
2023-06-29 | Vanguard Group Inc | 113.37M | 8.74B | 9.10% |
2023-06-29 | Capital World Investors | 80.93M | 6.24B | 6.50% |
2023-06-29 | State Street Corporation | 59.32M | 4.57B | 4.76% |
2023-06-29 | Capital Research Global Investors | 57.90M | 4.46B | 4.65% |
2023-06-29 | Dodge & Cox Inc | 33.98M | 2.62B | 2.73% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Total Stock Market Index Fund | 38.97M | 3.00B | 3.13% |
2023-09-29 | Income Fund of America Inc | 34.44M | 2.58B | 2.76% |
2023-06-29 | Vanguard 500 Index Fund | 29.70M | 2.29B | 2.38% |
2023-06-29 | Dodge & Cox Stock Fund | 24.24M | 1.87B | 1.95% |
2023-08-30 | Invesco ETF Tr-Invesco QQQ Tr, Series 1 ETF | 21.14M | 1.62B | 1.70% |
2023-09-29 | Washington Mutual Investors Fund | 20.14M | 1.51B | 1.62% |
Dividend | Date |
---|---|
0.77 | 2024-06-14 |
0.77 | 2024-03-14 |
0.75 | 2023-12-14 |
0.75 | 2023-09-15 |
0.75 | 2023-09-14 |
0.75 | 2023-06-14 |
Split | Date |
---|---|
2 : 1 | 2013-01-28 |
2 : 1 | 2007-06-25 |
2 : 1 | 2004-09-07 |
2 : 1 | 2002-03-08 |
2 : 1 | 2001-02-22 |
Because it sucks
Too bad the vaccine doesn’t help at all but enjoy the profits!
Fantastic! Great talking point for Trump to put teeth in rounding the corner on Covid.
Can it go up to a hundred tomorrow? Or maybe after a month?
Gilead: 'Failed' Remdesivir Solidarity Study Might Really Show Efficacy https://seekingalpha.com/article/4379587-gilead-failed-remdesivir-solidarity-study-might-really-show-efficacy
Once COVID progressed to respiratory failure requiring assisted ventilation, very likely an inflammatory phase has come into play.
Why this group was included in any analysis with the less sick patients in statistical analysis is unclear. I will attempt to exclude this group, using the limited data in the preprint, which says: ... 28-day mortality was 12% (39% if already ventilated at randomization, 10% otherwise).
Next, I am going to make the assumption, for modeling purposes, that those numbers also apply to the RDV group. If so, the above data suggest that roughly 5% of patients were on ventilators at study entry.
Using that estimate, I will next assume that the same mortality rate, 39%, that applied to the ventilated group as a whole applied to the RDV group.
That adjustment would bring the RDV mortality analysis from 10.97% to 248/2606, or 9.52%. (The denominator drops by 137, or 5% of the total RDV group; the numerator drops by 39% of 137).
This adjusted number, 9.52%, is only 85% of the 11.19% mortality rate for the placebo group. It is clinically meaningful.
So my take is that even with the many limitations of the study, the obvious study adjustment that should not have expected ventilated patients to have any benefit from RDV based on prior learnings is consistent with at least a clinically meaningful trend of RDV on mortality in COVID-19.
$GILD Strong earnings from Remdesivir in 2020 and 2021 will support strong rebound of #GILD back to $70s in a couple of weeks.
The worldwide shortage of Remdesivir apparently prompted many organizations like EU and WHO wanting to add chips to lower the price of Veklury in negotiating with $GILD.
Remdesivir functions effectively as nucleoside RNA polymerase inhibitor to suppress the virus reproduction. WHO Solidarity trials don’t record the timing from COVID-19 symptom to taking Remdesivir treatment! The truth is Remdesivir has to be taken as early as possible after respiratory symptoms show up. $GILD and FDA never touted Remdesivir may reduce the mortality rate but it helps patient fighting COVID-19 virus so as to REDUCE THE HOSPITALIZATION BY 4 DAYS significantly evidenced by the double blinded test result. The key is Remdesivir IS EFFECTIVE if it’s served TIMELY for COVID-19 patients within 48 hours of symptom appearance. $GILD will rebound definitely as there is no alternate to replace Remdesivir! All virus treatments need to be the cocktail approach like President Trump received and no one for now can decide “well, we throw the Remdesivir off from our COVID-19 toolbox according to WHO Solidarity trial non peer reviewed report!!!“.
“If you are a patient in the hospital with covid-19, your physician is going to want to give you remdesivir,” said Evan Seigerman, the Credit Suisse analyst who is tracking the drug’s progress and predicted up to $4.5 billion in sales in 2020 and up to $5 billion in 2021. After that, sales may decline with advent of a vaccine and possible new treatments such as monoclonal antibodies. “Remdesivir is the therapeutic of choice at the moment,” he said.
$GILD Post pandemic play w HCV
$GILD earnings surprise. Gonna hold it st this price into earnings this month.
“Covid-19 is the cherry on top” great reporting CNBC live in Hawaii making profit as well off COVID. Real drugs with 9%, 11% gain is $TCNNF $GFBIF $CFLBF after Mama Kamala pumped the decrim last night 🦠
$GILD $PNAS https://www.pnas.org/content/early/2020/10/06/2012294117 published oct 7th Remdesivir targets a structurally analogous region of the Ebola virus and SARS-CoV-2 polymerases
Panic panic sell sell sell just kidding. We are on the floor on the 5 year chart. This is a great starting position. I went all in after the tweet. $GILD
$GILD was waiting for the pullback. Thank y daddy trump for this xmas ‘rona blessing getyourbootytothepoll.com